Patents by Inventor KARINA DALSGAARD SØRENSEN

KARINA DALSGAARD SØRENSEN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MicroRNA-based method for early detection of prostate cancer in urine samples
    Patent number: 10400288
    Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.
    Type: Grant
    Filed: February 5, 2016
    Date of Patent: September 3, 2019
    Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbH
    Inventors: Anni Rønfeldt Thomsen, Jacob Christian Fredsøe, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
  • Microrna-based method for assessing the prognosis of a prostate cancer patient
    Patent number: 10358681
    Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, mi R-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, mi R-374b-5p, miR-615-3p and mi R-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: July 23, 2019
    Assignees: Aarhus Universitet, Region Midtjylland, QIAGEN GmbH
    Inventors: Anni Rønfeldt Thomsen, Helle Kristensen, Karina Dalsgaard Sørensen, Lars Kongsbak, Peter Mouritzen, Torben Ørntoft
  • Biomarkers for prostate cancer
    Patent number: 10106854
    Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: October 23, 2018
    Assignees: Aarhus Universitet, Region Midtjylland
    Inventors: Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Christa Haldrup
  • A MICRORNA-BASED METHOD FOR ASSESSING THE PROGNOSIS OF A PROSTATE CANCER PATIENT
    Publication number: 20180044737
    Abstract: The present application concerns a new in vitro method for assessing the prognosis of a prostate cancer patient, comprising measuring the expression level of at least two miRs selected from group of miRs consisting of: miR-106a-5p, miR-10b-5p, miR-133a-3p, miR-152-3p, miR-185-5p, miR-193a-5p, miR-221-3p, miR-23a-3p, miR-30d-3p, miR-326, miR-374b-5p, miR-615-3p and miR-625-3p in a RNA sample from prostate cells obtained from said patient, wherein a changed expression level of said at least 2 miRs, as compared to a reference expression profile, is indicative of the prognosis of said prostate cancer patient.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 15, 2018
    Applicant: Exiqon A/S
    Inventors: Anni RØNFELDT THOMSEN, Helle KRISTENSEN, Karina DALSGAARD SØRENSEN, Lars KONGSBAK, Peter MOURITZEN, Torben ØRNTOFT
  • MICRORNA-BASED METHOD FOR EARLY DETECTION OF PROSTATE CANCER IN URINE SAMPLES
    Publication number: 20180030542
    Abstract: The present application concerns a new in vitro method for assessing the risk that a subject suffers from prostate cancer.
    Type: Application
    Filed: February 5, 2016
    Publication date: February 1, 2018
    Inventors: Anni RØNFELDT THOMSEN, Jacob Christian FREDSØE, Karina DALSGAARD SØRENSEN, Lars KONGSBAK, Peter MOURITZEN, Torben ØRNTOFT
  • BIOMARKERS FOR PROSTATE CANCER
    Publication number: 20150152507
    Abstract: The present application concerns methods and tools for diagnosing prostate cancer and furthermore concerns methods and tools for prognosing disease progression of prostate cancer. The method comprises determining methylation level of the genes C1orf114, HAPLN3, AOX1, GAS6, ST6GALNAC3 and ZNF660 and comparing the result with a control, thus obtaining a response which is used for diagnosing a prostate cancer and/or for prognosing aspects of an individual suffering from prostate cancer.
    Type: Application
    Filed: June 14, 2013
    Publication date: June 4, 2015
    Inventors: Torben Falck Ørntoft, Karina Dalsgaard Sørensen, Christa Haldrup
  • MARKER OF PROSTATE CANCER
    Publication number: 20100303795
    Abstract: An SLC18A2 gene serves as a marker of prostate cancer. Methods are provided for diagnosing prostate cancer, predicting or prognosticating the disease outcome, predicting recurrence following surgery, and monitoring disease progression in an individual having prostate cancer. The methods relate to determining the methylation state of an SLC18A2 gene and/or determining the level of transcription or translation of the gene in a sample from the individual. Methods of treating prostate cancer are also provided. The invention also pertains to compositions and kits for use in the methods.
    Type: Application
    Filed: May 27, 2010
    Publication date: December 2, 2010
    Inventors: KARINA DALSGAARD SØRENSEN, TORBEN FALCK ØRNTOFT, LARS DYRSKJØT ANDERSEN